Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
|Slideshows|August 10, 2020
13 Psychiatric Drugs With Novel Mechanisms: A Timeline
Author(s)John J. Miller, MD
Some speculate the pharmaceutical industry has virtually abandoned new drug development in neuroscience with a few exceptions. However, it should be noted that progress has been made.
Advertisement
Advertisement
Related to this article
Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
FDA Shelves Fast-Track Drug Review Initiative
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and Schizophrenia
5